Ignite Creation Date:
2024-05-06 @ 7:49 PM
Last Modification Date:
2024-10-26 @ 3:14 PM
Study NCT ID:
NCT06143423
Status:
RECRUITING
Last Update Posted:
2023-11-22
First Post:
2023-11-16
Brief Title:
A Clinical Trial of AP026 TQA2226 for Injection in Adult Subjects
Sponsor:
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co Ltd
Organization:
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Phase I Clinical Trial to Evaluate AP026 TQA2226 for Injection in Adult Subjects After SingleMultiple Administration
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was a randomized double-blind placebo-controlled phase I clinical trial of AP026 TQA2226 for injection in adult healthy subjects which planned to recruit 74 healthy subjects The main purpose was to evaluate the safety and tolerance of AP026 TQA2226 for injection after single and multiple doses in healthy subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None